학술논문
454O A phase (Ph) I/II trial of the CXCR2 antagonist AZD5069 in combination with enzalutamide (ENZA) in patients (pts) with metastatic castration resistant prostate cancer (mCRPC)
Document Type
Abstract
Author
Source
In Annals of Oncology September 2022 33 Supplement 7:S745-S745
Subject
Language
ISSN
0923-7534